Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance
2024 Standout
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
2024 Standout
Works of Heimo Lagler being referenced
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
2021
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Heimo Lagler | 593 | 347 | 213 | 75 | 1.3k | |
| J. Guitard | 609 | 602 | 156 | 87 | 1.6k | |
| Christoph Steininger | 548 | 906 | 125 | 69 | 1.7k | |
| Hung‐Chin Tsai | 723 | 527 | 150 | 92 | 1.5k | |
| Selma Tobudic | 970 | 470 | 110 | 67 | 1.5k | |
| Sasheela Ponnampalavanar | 674 | 359 | 405 | 98 | 1.5k | |
| Babak Pourakbari | 661 | 501 | 119 | 116 | 1.5k | |
| Robert E. Van Scoy | 386 | 607 | 117 | 47 | 1.4k | |
| Kyung‐Hwa Park | 475 | 234 | 180 | 119 | 1.3k | |
| C. Arvieux | 634 | 669 | 186 | 99 | 1.7k | |
| Herman Chmel | 561 | 572 | 133 | 63 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...